Akums Drugs and Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?

Akums Drugs and Pharmaceuticals share price is trading close to its 52-week high of Rs 796.55, with Akums Drugs and Pharmaceuticals share price near Rs 759 on the NSE, nearly double its 52-week low of Rs 409.30. With a strong Q1 FY27 recovery following a mixed FY26, investors are asking whether this CDMO and pharmaceutical manufacturer is a stock to buy near its highs, a hold, or a sell.

This Akums Drugs and Pharmaceuticals stock analysis walks through the Q1 FY27 numbers, the mixed FY26 backdrop, valuation against the pharmaceutical CDMO sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.

Click Here – Get Free Investment Predictions

About Akums Drugs and Pharmaceuticals

Before deciding on Akums Drugs and Pharmaceuticals share price, it helps to understand the underlying business. Akums Drugs and Pharmaceuticals Ltd. is a contract development and manufacturing organisation (CDMO) serving pharmaceutical companies with formulation development and manufacturing services across a wide range of dosage forms.

As one of India's larger pharmaceutical CDMO players, Akums Drugs and Pharmaceuticals' results reflect the scale economics of contract manufacturing, with the most recent quarter showing a clear acceleration in profit growth after a softer full FY26 year.

Akums Drugs and Pharmaceuticals Share Price Today: Key Levels

The table below summarises where Akums Drugs and Pharmaceuticals share price stands right now against its recent trading range and market value.

Metric	Value
Akums Drugs CMP (NSE)	Rs 759.35
Akums Drugs CMP (BSE)	Rs 759.70
52-Week High	Rs 796.55
52-Week Low	Rs 409.30
Market Capitalisation	Approximately Rs 12,300 crore

Akums Drugs and Pharmaceuticals share price is trading close to its 52-week high, having nearly doubled from its 52-week low, reflecting strong investor confidence following the Q1 FY27 profit acceleration.

Check the Univest Screener for Live Stock Data

Akums Drugs and Pharmaceuticals Financial Performance

The Akums Drugs and Pharmaceuticals share price trend is closely tied to how these numbers evolve each quarter. Akums Drugs and Pharmaceuticals reported Q1 FY27 (June 2026 quarter) revenue of Rs 1,197.01 crore, up 13.9 percent year on year from Rs 1,050.76 crore, with net profit growing 56.1 percent year on year to Rs 100.98 crore from Rs 64.69 crore, a clear acceleration from the pace seen across FY26.

For the full year FY26, the company reported revenue of Rs 4,487.74 crore, up 7.6 percent year on year, but net profit fell 25.4 percent to Rs 256.40 crore from Rs 343.78 crore in FY25, a mixed year that the Q1 FY27 results suggest may be reversing.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 1,197.01 crore	Rs 100.98 crore	+13.9% revenue, +56.1% profit YoY
FY26 (full year)	Rs 4,487.74 crore	Rs 256.40 crore	+7.6% revenue, -25.4% profit YoY

Valuation Check: Is Akums Drugs and Pharmaceuticals Share Price Expensive?

Any view on Akums Drugs and Pharmaceuticals share price should start from these valuation multiples. Akums Drugs and Pharmaceuticals share price currently reflects a price to earnings ratio of about 42 times trailing earnings, a slight premium to the broader pharmaceutical CDMO sector average of roughly 38 times. The price to book ratio stands near 3.7 times, with return on equity at 7.70 percent.

Debt to equity of 0.05 is very low. Given the strong Q1 FY27 acceleration following the softer FY26 year, the current slight premium to the sector reflects the market's optimism that the recent quarter's improvement will continue, though this needs confirmation over further quarters.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Akums Drugs and Pharmaceuticals share price. Akums Drugs and Pharmaceuticals share price is currently positioned close to its 52-week high of Rs 796.55, nearly double its 52-week low of Rs 409.30, reflecting a very strong run over the past year, accelerated further by the Q1 FY27 results. A stock trading this close to its high, backed by strong recent profit growth, typically signals the market rewarding the improvement after a softer prior year.

Trading volumes remain heavy, so investors should track Akums Drugs and Pharmaceuticals share price alongside continued confirmation that the FY26 profit decline has truly reversed, rather than reacting to a single strong quarter alone at these technical levels.

Download the Univest iOS App or Univest Android App to track Akums Drugs and Pharmaceuticals' live price and technical levels.

Shareholding Pattern

Shifts here can influence Akums Drugs and Pharmaceuticals share price more than headline news on some sessions. Akums Drugs and Pharmaceuticals is a promoter-led CDMO and pharmaceutical manufacturing company. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Akums Drugs and Pharmaceuticals

• Strong Q1 FY27 acceleration: Profit growth of 56.1 percent year on year in the most recent quarter marks a clear improvement from the softer FY26 year.
• Scale as a leading CDMO player: As one of India's larger pharmaceutical contract manufacturers, Akums Drugs and Pharmaceuticals benefits from scale economics across its formulation and manufacturing capabilities.
• Very low financial leverage: A debt to equity ratio of just 0.05 gives the company significant financial flexibility.
• Strong stock performance over the past year: The stock has nearly doubled from its 52-week low, reflecting sustained investor confidence.

Risks and Factors to Watch

• Mixed FY26 backdrop: Full-year FY26 profit fell 25.4 percent despite revenue growth, and the Q1 FY27 acceleration needs to be sustained over further quarters to confirm a genuine reversal.
• Slight premium valuation to sector: A 42x PE against a 38x pharmaceutical CDMO sector average leaves limited room for disappointment if the recent quarter's momentum does not continue.
• CDMO business margin sensitivity: As a contract manufacturer, margins can be sensitive to input costs, customer mix and pricing negotiations with pharmaceutical clients.
• Regulatory and quality compliance risk: As a pharmaceutical manufacturer, the company is subject to regulatory scrutiny and quality compliance requirements that carry inherent business risk.

Akums Drugs and Pharmaceuticals Share Price Target: What the Data Suggests

Until then, Akums Drugs and Pharmaceuticals share price remains best tracked through live, verified data rather than a single fixed number. Akums Drugs and Pharmaceuticals does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company showing a strong Q1 FY27 acceleration following a mixed FY26 year, trading close to its 52-week high.

Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.

Akums Drugs and Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Akums Drugs and Pharmaceuticals share price right now. The Akums Drugs and Pharmaceuticals buy or sell decision depends on whether the Q1 FY27 acceleration marks a genuine turn from the softer FY26 year.

The case for buying: Investors who believe the Q1 FY27 profit acceleration signals a genuine reversal from FY26's decline may find the company's scale and low leverage attractive despite the stock trading close to its high.

The case for holding: Existing shareholders who already track Akums Drugs and Pharmaceuticals' CDMO business may prefer to stay invested and monitor continued execution.

The case for waiting: Investors wanting to see the Q1 FY27 acceleration confirmed over further quarters before committing fresh capital may prefer to wait for that confirmation.

Weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.

Conclusion

Akums Drugs and Pharmaceuticals share price reflects a leading CDMO and pharmaceutical manufacturer showing a strong Q1 FY27 profit acceleration following a mixed FY26 year, trading close to its 52-week high at a slight premium to the pharmaceutical CDMO sector. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is Akums Drugs and Pharmaceuticals a good stock to buy right now?

Ans. Akums Drugs and Pharmaceuticals grew Q1 FY27 profit 56.1 percent year on year, a clear acceleration following a mixed FY26 in which profit fell 25.4 percent. This may appeal to investors who believe the recent quarter marks a genuine turnaround, though this needs confirmation over further quarters.

Q2. What is the Akums Drugs and Pharmaceuticals share price today?

Ans. Akums Drugs and Pharmaceuticals share price is trading around Rs 759 on the NSE, close to its 52-week high of Rs 796.55. The stock's 52-week low is Rs 409.30.

Q3. What is the Akums Drugs and Pharmaceuticals share price target?

Ans. Akums Drugs and Pharmaceuticals does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.

Q4. What does Akums Drugs and Pharmaceuticals do?

Ans. Akums Drugs and Pharmaceuticals is a contract development and manufacturing organisation serving pharmaceutical companies with formulation development and manufacturing services.

Q5. What is Akums Drugs and Pharmaceuticals' market capitalisation and PE ratio?

Ans. Akums Drugs and Pharmaceuticals has a market capitalisation of approximately Rs 12,300 crore and trades at a price to earnings ratio of about 42 times, a slight premium to the pharmaceutical CDMO sector average PE of roughly 38 times.

Q6. Why did Akums Drugs and Pharmaceuticals' profit fall in FY26?

Ans. Akums Drugs and Pharmaceuticals' full-year FY26 net profit fell 25.4 percent to Rs 256.40 crore despite 7.6 percent revenue growth, though the most recent Q1 FY27 quarter showed a strong 56.1 percent profit acceleration.